Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Maurizio Fava, M.D.

Co-Author

This page shows the publications co-authored by Maurizio Fava and Cristina Cusin.
Connection Strength

5.824
  1. Cusin C, Ionescu DF, Pavone KJ, Akeju O, Cassano P, Taylor N, Eikermann M, Durham K, Swee MB, Chang T, Dording C, Soskin D, Kelley J, Mischoulon D, Brown EN, Fava M. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry. 2017 Jan; 51(1):55-64.
    View in: PubMed
    Score: 0.773
  2. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 2012 Aug; 169(8):868-9.
    View in: PubMed
    Score: 0.569
  3. Sakurai H, Jain F, Foster S, Pedrelli P, Mischoulon D, Fava M, Cusin C. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. J Affect Disord. 2020 Nov 01; 276:660-666.
    View in: PubMed
    Score: 0.247
  4. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1604.
    View in: PubMed
    Score: 0.246
  5. Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.243
  6. Cusin C, Sakurai H, Bentley K, Pedrelli P, Foster S, Fava M, Mischoulon D. All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment. Am J Psychiatry. 2020 02 01; 177(2):173-174.
    View in: PubMed
    Score: 0.239
  7. Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, Trinh NH, Bernard R, Boyden S, Iqbal SZ, Wilkinson ST, Mathew SJ, Mischoulon D, Fava M, Cusin C. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108.
    View in: PubMed
    Score: 0.230
  8. Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.222
  9. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.218
  10. Ionescu DF, Bentley KH, Eikermann M, Taylor N, Akeju O, Swee MB, Pavone KJ, Petrie SR, Dording C, Mischoulon D, Alpert JE, Brown EN, Baer L, Nock MK, Fava M, Cusin C. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. J Affect Disord. 2019 01 15; 243:516-524.
    View in: PubMed
    Score: 0.217
  11. Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C, Ionescu DF, Alpert JE, Soskin DP, Fava M. Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]. J Affect Disord. 2018 02; 227:198.
    View in: PubMed
    Score: 0.205
  12. Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
    View in: PubMed
    Score: 0.203
  13. Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C, Ionescu DF, Alpert JE, Soskin DP, Fava M. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017 Jan 15; 208:6-14.
    View in: PubMed
    Score: 0.190
  14. Ionescu DF, Swee MB, Pavone KJ, Taylor N, Akeju O, Baer L, Nyer M, Cassano P, Mischoulon D, Alpert JE, Brown EN, Nock MK, Fava M, Cusin C. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. J Clin Psychiatry. 2016 06; 77(6):e719-25.
    View in: PubMed
    Score: 0.185
  15. Ionescu DF, Fava M, Kim DJ, Baer L, Shelton RC, Cusin C. A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. Ther Adv Psychopharmacol. 2016 Feb; 6(1):4-12.
    View in: PubMed
    Score: 0.181
  16. Cusin C, Iovieno N, Iosifescu DV, Nierenberg AA, Fava M, Rush AJ, Perlis RH. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013 Jul; 74(7):e636-41.
    View in: PubMed
    Score: 0.152
  17. Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, Fava M. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom. 2012; 81(5):312-4.
    View in: PubMed
    Score: 0.142
  18. Perlis RH, Cusin C, Fava M. Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder. Psychol Med. 2014 May; 44(7):1361-7.
    View in: PubMed
    Score: 0.139
  19. Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom. 2007; 76(1):40-6.
    View in: PubMed
    Score: 0.097
  20. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis RH. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry. 2007 Jan; 68(1):52-7.
    View in: PubMed
    Score: 0.097
  21. Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem. 2005; 5(11):1077-86.
    View in: PubMed
    Score: 0.084
  22. Cassano P, Soares CN, Cusin C, Mascarini A, Cohen LS, Fava M. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine. Psychother Psychosom. 2005; 74(6):362-5.
    View in: PubMed
    Score: 0.084
  23. Petibon Y, Alpert NM, Ouyang J, Pizzagalli DA, Cusin C, Fava M, El Fakhri G, Normandin MD. PET imaging of neurotransmission using direct parametric reconstruction. Neuroimage. 2020 Jul 15; 221:117154.
    View in: PubMed
    Score: 0.062
  24. Dichtel LE, Carpenter LL, Nyer M, Mischoulon D, Kimball A, Deckersbach T, Dougherty DD, Schoenfeld DA, Fisher L, Cusin C, Dording C, Trinh NH, Pedrelli P, Yeung A, Farabaugh A, Papakostas GI, Chang T, Shapero BG, Chen J, Cassano P, Hahn EM, Rao EM, Brady RO, Singh RJ, Tyrka AR, Price LH, Fava M, Miller KK. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020 Jul 14; appiajp202019080844.
    View in: PubMed
    Score: 0.062
  25. Dichtel LE, Nyer M, Dording C, Fisher LB, Cusin C, Shapero BG, Pedrelli P, Kimball AS, Rao EM, Mischoulon D, Fava M, Miller KK. Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study. J Clin Psychiatry. 2020 06 09; 81(4).
    View in: PubMed
    Score: 0.061
  26. Jha MK, Fava M, Minhajuddin A, Chin Fatt C, Mischoulon D, Wakhlu N, Trombello JM, Cusin C, Trivedi MH. Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. Psychol Med. 2020 Mar 06; 1-9.
    View in: PubMed
    Score: 0.060
  27. Kimball A, Dichtel LE, Nyer MB, Mischoulon D, Fisher LB, Cusin C, Dording CM, Trinh NH, Yeung A, Haines MS, Sung JC, Pinna G, Rasmusson AM, Carpenter LL, Fava M, Klibanski A, Miller KK. The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause. Psychoneuroendocrinology. 2020 02; 112:104512.
    View in: PubMed
    Score: 0.059
  28. Sakurai H, L Carpenter L, R Tyrka A, Price LH, I Papakostas G, Dording CM, Yeung AS, Cusin C, Ludington E, Bernard-Negron R, Fava M, Mischoulon D. Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. J Affect Disord. 2020 Feb 01; 262:118-125.
    View in: PubMed
    Score: 0.059
  29. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.058
  30. Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.055
  31. Cassano P, Petrie SR, Mischoulon D, Cusin C, Katnani H, Yeung A, De Taboada L, Archibald A, Bui E, Baer L, Chang T, Chen J, Pedrelli P, Fisher L, Farabaugh A, Hamblin MR, Alpert JE, Fava M, Iosifescu DV. Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. Photomed Laser Surg. 2018 Dec; 36(12):634-646.
    View in: PubMed
    Score: 0.055
  32. Iovieno N, Shelton RC, Petrie SR, Cusin C, Fava M, Papakostas GI. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. J Clin Psychiatry. 2018 Jan/Feb; 79(1).
    View in: PubMed
    Score: 0.052
  33. Mischoulon D, De Jong MF, Vitolo OV, Cusin C, Dording CM, Yeung AS, Durham K, Parkin SR, Fava M, Dougherty DD. Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study. J Psychiatr Res. 2015 Nov; 70:98-105.
    View in: PubMed
    Score: 0.044
  34. Cassano P, Cusin C, Mischoulon D, Hamblin MR, De Taboada L, Pisoni A, Chang T, Yeung A, Ionescu DF, Petrie SR, Nierenberg AA, Fava M, Iosifescu DV. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry J. 2015; 2015:352979.
    View in: PubMed
    Score: 0.044
  35. Iscan Z, Jin TB, Kendrick A, Szeglin B, Lu H, Trivedi M, Fava M, McGrath PJ, Weissman M, Kurian BT, Adams P, Weyandt S, Toups M, Carmody T, McInnis M, Cusin C, Cooper C, Oquendo MA, Parsey RV, DeLorenzo C. Test-retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. Hum Brain Mapp. 2015 Sep; 36(9):3472-85.
    View in: PubMed
    Score: 0.043
  36. Dillon DG, Wiecki T, Pechtel P, Webb C, Goer F, Murray L, Trivedi M, Fava M, McGrath PJ, Weissman M, Parsey R, Kurian B, Adams P, Carmody T, Weyandt S, Shores-Wilson K, Toups M, McInnis M, Oquendo MA, Cusin C, Deldin P, Bruder G, Pizzagalli DA. A computational analysis of flanker interference in depression. Psychol Med. 2015 Aug; 45(11):2333-44.
    View in: PubMed
    Score: 0.043
  37. Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, Baer L, Clain AJ, Fava M, Mischoulon D. Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. Asian J Psychiatr. 2015 Feb; 13:23-9.
    View in: PubMed
    Score: 0.042
  38. Pedrelli P, Nyer M, Holt D, Bakow BR, Fava M, Baer L, Cassiello C, Mulligan M, Cusin C, Farabaugh A. Correlates of irritability in college students with depressive symptoms. J Nerv Ment Dis. 2013 Nov; 201(11):953-8.
    View in: PubMed
    Score: 0.039
  39. Perlis RH, Purcell S, Fagerness J, Cusin C, Yamaki L, Fava M, Smoller JW. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry. 2007 Sep 01; 62(5):536-40.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.